COSM vs XTLB vs NUVB vs HROW

For growth investors, Nuvation Bio Inc.

(NUVB) is the stronger pick with 699. 0% revenue growth year-over-year, versus 2. 0% for Cosmos Health Inc. (COSM). Analysts rate Nuvation Bio Inc. (NUVB) a "Buy" — based on 9 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Harrow Health, Inc.

(HROW) delivered a total return of +378. 0%, compared to -94. 5% for Cosmos Health Inc. (COSM). Over 10 years, the gap is even starker: HROW returned +914. 3% versus XTLB's -87. 3%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), XTL Biopharmaceuticals Ltd.

(XTLB) is the lower-risk stock at 1. 71β versus Harrow Health, Inc. 's 2. 13β — meaning HROW is approximately 25% more volatile than XTLB relative to the S&P 500. On balance sheet safety, XTL Biopharmaceuticals Ltd. (XTLB) carries a lower debt/equity ratio of 3% versus 5% for Harrow Health, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Nuvation Bio Inc.

(NUVB) is pulling ahead at 699. 0% versus 2. 0% for Cosmos Health Inc. (COSM). On earnings-per-share growth, the picture is similar: Nuvation Bio Inc. grew EPS 71. 6% year-over-year, compared to 45. 6% for Cosmos Health Inc.. Over a 3-year CAGR, HROW leads at 45. 4% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Harrow Health, Inc.

(HROW) is the more profitable company, earning -1. 9% net margin versus -325. 3% for Nuvation Bio Inc. — meaning it keeps -1. 9% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: HROW leads at 11. 2% versus -481. 6% for XTLB. At the gross margin level — before operating expenses — NUVB leads at 86. 6%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

Analyst consensus price targets imply the most upside for NUVB: 157.

3% to $12. 40.

In this comparison, COSM (92.

4% yield) pays a dividend. XTLB, NUVB, HROW do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Cosmos Health Inc.

(COSM) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (92. 4% yield). Nuvation Bio Inc. (NUVB) carries a higher beta of 2. 04 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (COSM: +37. 8%, NUVB: -51. 8%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: COSM is a small-cap income-oriented stock; XTLB is a small-cap quality compounder stock; NUVB is a small-cap high-growth stock; HROW is a small-cap high-growth stock. COSM pays a dividend while XTLB, NUVB, HROW do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.